Trial site
Centre Hospitalier d'Auxerre
Auxerre, Yonne 89000, FranceNot linked to an institution yet
- 18running trials
- 7closed trials
The trials here
What the 25 trials at this site are about, from their registry records.
- Phase
- Phase 312 trials
- Phase 210 trials
- Phase 2/32 trials
- Status
- Recruiting9 trials
- Active, not recruiting7 trials
- Completed4 trials
- Terminated3 trials
- Not yet recruiting2 trials
- Lead sponsor
- UNICANCER7 trials
- Unicancer3 trials
- Assistance Publique Hopitaux De Paris2 trials
- Centre Hospitalier Universitaire De Dijon2 trials
- Centre Hospitalier Universitaire Dijon2 trials
- and 8 more
Running trials
Not yet recruiting
Aspirin in Acute Pneumonia in the Elderly: a Multicenter, Double-blind, Randomized, Placebo-controlled Trial.
NCT06774846· Phase 3· Centre Hospitalier Universitaire Dijon· Source
Not yet recruiting
Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases
NCT07359456· Phase 2· UNICANCER· Source
Not yet recruiting
Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer
NCT07150403· Phase 2· Federation Francophone de Cancerologie Digestive· Source
Recruiting
Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy
NCT06680596· Phase 2· UNICANCER· Source
Recruiting
Beta-blOckers discoNtinuation in patients presenting heart FaIlure with REcovered left ventricular ejection fraction
2023-508798-94-00· Phase 3· Assistance Publique Hopitaux De Paris· Source
Recruiting
PRODIGE 90 - FFCD 22024 - PREDIR-NEOREC - Neoadjuvant dostarlimab with short course radiotherapy in a watch-and-wait strategy for microsatellite unstable or mismatch repair-deficient locally advanced rectal cancer patients: a randomized phase II trial
2024-510772-20-00· Phase 2· Centre Hospitalier Universitaire De Dijon· Source
Recruiting
Colchicine Versus Placebo in Acute Myocarditis Patients
NCT05855746· Phase 3· Assistance Publique - Hôpitaux de Paris· Source
Recruiting
CARE : Impact of Regorafenib in combination with multimodal metronomic chemotherapy (cyclophosphamide, capecitabine, and low-dose aspirin) on progression-free survival compared with standard Regorafenib for the treatment of chemo-resistant metastatic colorectal cancers
2023-509761-21-00· Phase 3· Centre Hospitalier Regional Universitaire· Source
Recruiting
Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority Study
NCT05692999· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source
Active, not recruiting
Reduction of hormone therapy duration in women with hormonesensitive breast cancer at very low risk of metastatic recurrence
NCT05297617· Phase 2· Unicancer· Source
Active, not recruiting
Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line
NCT05201547· Phase 3· ARCAGY/ GINECO GROUP· Source
Recruiting
Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary
NCT04325425· Phase 2· Centre Hospitalier Universitaire Dijon· Source
Recruiting
Randomized phase 3 trial comparing FOLFOX to gemcitabine in metastatic first-line in patients with pancreatic adenocarcinoma and non-fit for FOLFIRINOX (GEMFOX)
NCT04167007· Phase 2/3· Assistance Publique Hopitaux De Paris· Source
Active, not recruiting
Study comparing two standard treatments as initial metastatic treatment among patients with visceral metastasis of ER+ HER2- breast cancer, high burden disease: chemotherapy and combination of hormonotherapy with abemaciclib.
NCT04158362· Phase 3· Unicancer· Source
Active, not recruiting
Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy
NCT03977194· Phase 3· Intergroupe Francophone de Cancerologie Thoracique· Source
Completed
IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting
NCT02967289· Phase 3· UNICANCER· Source
Completed
PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection
NCT03079011· Phase 3· UNICANCER· Source
Active, not recruiting
PRODIGE 34 - ADAGE: Randomised phase III study evaluating adjuvant chemotherapy after resection of stage III colon adenocarcinoma in patients aged 70 and older
NCT02355379· Phase 2· Fondation Franc.Cancerologie Digestive· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error